Status:
TERMINATED
Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection
Lead Sponsor:
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Collaborating Sponsors:
Attikon Hospital
Conditions:
Pulmonary Infection
Covid-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is a phase II, parallel, prospective, randomized, double-blind, placebo controlled trial. The present study will aim to address the efficacy and safety of acute administration of triiodothy...
Detailed Description
It seems that thyroid hormone is critical in the response to body injury and is now considered as potential pharmaceutical intervention to limit acute tissue injury. TH (via its regulation of stress i...
Eligibility Criteria
Inclusion
- Patients diagnosed with pulmonary infection due to COVID-19, admitted in ICU and require mechanical ventilation or ECMO
- Male and female with Age\>18 years old
- Signed informed consent from patient or relatives
Exclusion
- Pregnant or breast-feeding women
- Severe systemic disease (cancer, auto-immune etc) before infection accompanied by reduced life expectancy \<6 months
- Participation in another trial of an investigational drug or device
- Corticosteroid Use before initiation of treatment
- Sympathomimetic Use before initiation of treatment (epinephrine, norepinephrine, dobutamine, dopamine, phenylephrine)
Key Trial Info
Start Date :
May 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 19 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04348513
Start Date
May 29 2020
End Date
April 19 2021
Last Update
September 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikon University General Hospital
Haidari/Athens, Greece, 12462